NeoImmuneTech 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Luke Yun Oh

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	3.7yrs
이사회 평균 재임 기간	2.3yrs

최근 관리 업데이트

Recent updates

Companies Like NeoImmuneTech (KOSDAQ:950220) Could Be Quite Risky

Aug 13

Will NeoImmuneTech (KOSDAQ:950220) Spend Its Cash Wisely?

Mar 22

CEO

Luke Yun Oh

less than a year

테뉴어

Dr. Luke Yun Suk Oh Ph. D. is President of NeoImmuneTech, Inc. from January 15, 2024 and serves as its Chief Executive Officer since March 29, 2024 and serves as its Chairman since 2024. Dr. Oh is an exper...

리더십 팀

이름	위치	테뉴어	보상	소유권
Luke Yun Oh	President	less than a year	데이터 없음	데이터 없음
Tae Woo Kim	Chief Financial Officer	no data	데이터 없음	데이터 없음
Goongjin Namgoong	Chief Operating Officer	4.8yrs	데이터 없음	데이터 없음
Byung Lee	Chief Scientific Officer	3.7yrs	데이터 없음	데이터 없음

3.7yrs

평균 재임 기간

경험이 풍부한 관리: A950220 의 관리팀은 경험 ( 3.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Luke Yun Oh	President	less than a year	데이터 없음	데이터 없음
Rafi Ahmed	Member of Scientific Advisory Board	5yrs	데이터 없음	데이터 없음
Soo-Hyoung Kang	Director	no data	데이터 없음	데이터 없음
Jin-Hyoung Kang	Director	3.5yrs	데이터 없음	데이터 없음
Sung-June Hong	Director	less than a year	데이터 없음	데이터 없음
Richard Kim	Member of Scientific Advisory Board	2.3yrs	데이터 없음	데이터 없음
Keith Watson	Member of Scientific Advisory Board	2.3yrs	데이터 없음	데이터 없음
Hyunseok Kang	Member of Scientific Advisory Board	2.3yrs	데이터 없음	데이터 없음
Young Chae	Member of Scientific Advisory Board	2.3yrs	데이터 없음	데이터 없음
Benny Chen	Member of Scientific Advisory Board	1.3yrs	데이터 없음	데이터 없음
Su-Hyung Park	Member of Scientific Advisory Board	1.3yrs	데이터 없음	데이터 없음
Choonggoo Kang	Director	less than a year	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

경험이 풍부한 이사회: A950220 의 이사회는 경험(평균 재직 기간 2.3 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

NeoImmuneTech 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

NeoImmuneTech, Inc. Appoints Luke Oh as President

Neoimmunetech, Inc. Appoints Benny J. Chen and Su-Hyung Park to Its Scientific Advisory Board

No independent directors

NeoImmuneTech, Inc. Appoints New Members to its Scientific Advisory Board

Recent updates

New minor risk - Share price stability

Companies Like NeoImmuneTech (KOSDAQ:950220) Could Be Quite Risky

NeoImmuneTech's New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors (CPI) in Immuno-Oncology

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

Will NeoImmuneTech (KOSDAQ:950220) Spend Its Cash Wisely?

New minor risk - Share price stability

NeoImmuneTech, Inc. Appoints Luke Oh as President

Fda Grants Orphan Drug Designation to Neoimmunetech's Nt-I7 for the Treatment of Acute Radiation Syndrome

New minor risk - Share price stability

Neoimmunetech, Inc. Appoints Benny J. Chen and Su-Hyung Park to Its Scientific Advisory Board

No independent directors

New Evidence of NeoImmuneTech's NT-I7 Clinical Efficacy in Combination with Pembrolizumab in Relapsed/Refractory (R/R) Gastrointestinal Tumors

NeoImmuneTech, Inc. Appoints New Members to its Scientific Advisory Board

NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity

NeoImmuneTech, Inc.'s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors

No independent directors

Neoimmunetech Demonstrates Nt-I7’S Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine At Aacr 2022

NeoImmuneTech, Inc. Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 Checkpoint Inhibitor in High-Risk Skin Cancers

NeoImmuneTech, Inc. Announces the Publication of Preclinical Data Evaluating Lead Asset NT-I7

NeoImmuneTech, Inc. announced that it has received $4.7 million in funding from Hefei SPARK Venture Capital Management Co., Ltd., Kindstar Global (Beijing) Technology, Inc.

NeoImmuneTech, Inc. Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting

Neoimmunetech to Present At Society for Neuro-Oncology

NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection

NeoImmuneTech, Inc. Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)

NeoImmuneTech, Inc. Announces First Patient Dosed in the Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy

CEO

테뉴어

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간